About the project
ROSA 4 is a cross-sectional study based on data from electronic patient records of approximately 11,500 patients diagnosed with diabetes. Data collection was conducted in 2015 and the first quarter of 2016. 282 general practitioners participated, distributed across 77 medical practices in parts of Oslo and Akershus, in Sandnes in Rogaland, in the districts of Laksevåg and Fyllingsdalen in Bergen, Fjell municipality in Hordaland, and in Salten in Nordland.
The quality of treatment is measured against national guidelines from 2009 and compared with data from a similar study conducted in 2005. The information is also linked to central registries. The study will therefore be able to provide answers to many central health questions. ROSA 4 will, among other things, assess the quality of treatment for patients with diabetes, the interaction between general practitioners and hospital clinics, and whether treatment is influenced by the patient's ethnic background, socio-economic position, or place of residence. After 5 and 10 years, morbidity and causes of death in these patients will be compared with the general population.
The project's main page is published by Noklus (in Norwegian).
Objectives
To investigate and assess:
- the quality of diabetes treatment in Norway in 2014
- trends in treatment quality from 2005 to 2014
- whether patients are treated at the appropriate level in the healthcare system
- whether treatment quality is influenced by the patient's ethnic background, socioeconomic position, or place of residence
- morbidity and mortality in individuals with diabetes compared to the general population.
Sub-projects at UiO
- Type 2 diabetes, gender, and ethnicity (norwegian)
- Type 2 diabetes: effective interaction? (norwegian)
- What characterizes those who develop diabetes at a young age? (norwegian)
Financing
Data collection was funded by the Norwegian Diabetes Association, Northern Norway Regional Health Authority, Western Norway Regional Health Authority, University of Oslo, and a consortium of 6 pharmaceutical companies (AstraZeneca, Boehring-Ingelheim, Eli Lilly, MSD, NovoNordisk, and Sanofi Aventis).
Sub-projects have separate financing by the Norwegian Research Fund for General Practice and the Extra Foundation/Norske Kvinners Sanitetsforening.
Cooperation
- Noklus (The Norwegian Organization for Quality Improvement of Laboratory Examinations)
- University of Bergen
- University of Oslo
- Oslo University Hospital
- Nordland Hospital Bodø
- The Norwegian Diabetes Association.
Project start and finish
2015 -